Cargando…

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside

BACKGROUND: To accelerate the progress towards onchocerciasis elimination, a macrofilaricidal drug that kills the adult parasite is urgently needed. Emodepside has shown macrofilaricidal activity against a variety of nematodes and is currently under clinical development for the treatment of onchocer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assmus, Frauke, Hoglund, Richard M., Monnot, Frédéric, Specht, Sabine, Scandale, Ivan, Tarning, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912909/ https://www.ncbi.nlm.nih.gov/pubmed/35271567 http://dx.doi.org/10.1371/journal.pntd.0010219

Ejemplares similares

Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects
por: Gillon, Jean‐Yves, et al.
Publicado: (2021)

Onchocerciasis drug development: from preclinical models to humans
por: Ngwewondo, Adela, et al.
Publicado: (2021)

Development of emodepside as a possible adulticidal treatment for human onchocerciasis—The fruit of a successful industrial–academic collaboration
por: Krücken, Jürgen, et al.
Publicado: (2021)

Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside
por: Hübner, Marc P., et al.
Publicado: (2021)

Evaluation of emodepside in laboratory models of human intestinal nematode and schistosome infections
por: Karpstein, Tanja, et al.
Publicado: (2019)

Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis
por: Bah, Germanus S., et al.
Publicado: (2021)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis
por: Panjasawatwong, Navarat, et al.
Publicado: (2020)

Adverse Drug Reactions After Administration of Emodepside/Praziquantel (Profender®) in an MDR1-Mutant Australian Shepherd Dog: Case Report
por: Gaens, Daniela, et al.
Publicado: (2019)

Safety of concurrent treatment of cats with fluralaner and emodepsid–praziquantel
por: Walther, Feli M., et al.
Publicado: (2016)

Natural variation in Caenorhabditis elegans responses to the anthelmintic emodepside
por: Wit, Janneke, et al.
Publicado: (2021)

Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats
por: Traversa, Donato, et al.
Publicado: (2022)

Erratum to: Safety of concurrent treatment of cats with fluralaner and emodepsid-praziquantel
por: Walther, Feli M., et al.
Publicado: (2016)

Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?
por: Chandler, Rebecca E.
Publicado: (2018)

Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis
por: Johnston, Kelly L., et al.
Publicado: (2014)

Worms take to the slo lane: a perspective on the mode of action of emodepside
por: Holden-Dye, Lindy, et al.
Publicado: (2012)

Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases
por: Twum-Danso, Nana AY
Publicado: (2003)

Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
por: Mackenzie, Charles D, et al.
Publicado: (2003)

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers
por: Chotsiri, Palang, et al.
Publicado: (2017)

Response to “Pharmacometric Approach to Evaluate Drug Dosing Adherence”
por: Ding, Junjie, et al.
Publicado: (2020)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
por: Mencke, Norbert, et al.
Publicado: (2023)

Supporting Drug Development for Neglected Tropical Diseases Using Mathematical Modeling
por: Walker, Martin, et al.
Publicado: (2021)

A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan
por: Hoglund, Richard M, et al.
Publicado: (2012)

Onchocerciasis
Publicado: (1911)

Navigating the way to onchocerciasis elimination: the feasibility and affordability of Onchocerciasis Elimination Mapping
por: Hamill, Louise, et al.
Publicado: (2022)

A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
por: Sjögren, Erik, et al.
Publicado: (2021)

Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon
por: Boussinesq, Michel, et al.
Publicado: (2003)

Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis
por: Haselow, Nancy J, et al.
Publicado: (2003)

Research for new drugs for elimination of onchocerciasis in Africa
por: Kuesel, Annette C.
Publicado: (2016)

An Integrated Multiomics Approach to Identify Candidate Antigens for Serodiagnosis of Human Onchocerciasis
por: McNulty, Samantha N., et al.
Publicado: (2015)

Diethylcarbamazine mediated potentiation of emodepside induced paralysis requires TRP-2 in adult Brugia malayi
por: Kashyap, Sudhanva S., et al.
Publicado: (2022)

2) Onchocerciasis
por: Tada, Isao
Publicado: (2015)

3) Onchocerciasis
por: Tada, Isao
Publicado: (2015)

Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria
por: Jamsen, Kris M, et al.
Publicado: (2012)

Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
por: Wattanakul, Thanaporn, et al.
Publicado: (2021)

Report of a Scientific Working Group on Serious Adverse Events following Mectizan(® ) treatment of onchocerciasis in Loa loa endemic areas
Publicado: (2003)

Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs
por: Chairat, Kalayanee, et al.
Publicado: (2018)

Preclinical and Clinical Characteristics of the Trichuricidal Drug Oxantel Pamoate and Clinical Development Plans: A Review
por: Palmeirim, Marta S., et al.
Publicado: (2021)

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_0cc5tolcj5nd5d3db2f0mc0dj5